News

Adcendo Achieves Milestone with FDA Clearance for ADCE-D01 Trial

Adcendo Achieves Milestone with FDA Clearance for ADCE-D01 Trial

FDA Clearance of ADCE-D01 Trial Marks Step Forward for Adcendo

Adcendo, a pioneering biotech company, has announced a significant milestone with the US Food and Drug Administration (FDA) clearing its Investigational New Drug (IND) application for the promising molecule ADCE-D01. This first-in-human clinical trial, known as the ADCElerate-01 Trial, aims to evaluate the safety and efficacy of this innovative antibody-drug conjugate (ADC) targeting uPARAP, which is notably overexpressed in various mesenchymal cancers, particularly soft tissue sarcomas (STS).

The Significance of ADCE-D01

ADCE-D01 is designed as a groundbreaking treatment targeting the uPARAP receptor, a receptor significantly involved in the pathology of mesenchymal cancers. Traditional therapies for metastatic soft tissue sarcoma often fall short, making the introduction of ADCE-D01 crucial for patients who desperately lack effective treatment options. This ADC is expected to demonstrate improved therapeutic outcomes for individuals suffering from advanced stages of these aggressive tumors.

Study Overview and Objectives

The Phase I/II ADCElerate-01 trial will enroll patients diagnosed with metastatic and/or unresectable STS to assess the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a standalone treatment. The primary focus of the study will be on determining the maximum tolerated dose and the overall safety profile of the drug, along with its recommended dosing schedules. Secondary objectives include detailed pharmacokinetics assessments and initial efficacy evaluations.

Expert Insights on ADCE-D01

Dr. Lone Ottesen, the Chief Medical Officer of Adcendo, emphasized the potential of uPARAP as a target for ADC therapy in mesenchymal cancers. She noted its high overexpression in various STS subtypes, alongside low expression in healthy tissues, making it an ideal candidate for targeted therapy. This IND clearance is not just a regulatory accomplishment; it carries significant implications for future cancer treatments and the patients who are in dire need of effective solutions.

Research and Development at Adcendo

In addition to ADCE-D01, Adcendo ApS is committed to developing a robust pipeline of first-in-class ADCs tailored for confrontations against various cancers that currently have limited treatment options. Earlier this year, the company secured a substantial funding boost, raising 98 million euros in a Series A extension financing round. These funds are earmarked to push their innovative therapies through clinical trials and into the hands of patients sooner.

Collaboration with Medical Experts

As part of the ADCElerate-01 trial, renowned experts such as Prof. Patrick Schöffski from the University Hospitals and KU Leuven have joined the team to take on the role of principal investigator. He expressed his enthusiasm regarding the unique biological profile of uPARAP and the promising pre-clinical data supporting ADCE-D01. Their collaborative effort aims to bring a transformative ADC treatment option to the forefront for patients battling soft tissue sarcoma.

About Adcendo ApS

Founded with a mission to reshape cancer therapies, Adcendo ApS remains resolute in their dedication to developing state-of-the-art antibody-drug conjugates aimed at addressing the dire needs in oncological healthcare. The company continues to collaborate with leading experts in the field, striving to make tangible impacts for patients globally.

Frequently Asked Questions

What does the FDA clearance of ADCE-D01 mean for patients?

The FDA clearance allows for the commencement of a clinical trial, offering patients with metastatic soft tissue sarcoma access to potentially groundbreaking therapy that targets their specific condition.

How does ADCE-D01 work?

ADCE-D01 targets the uPARAP receptor, which is overexpressed in various mesenchymal cancers, and aims to deliver therapeutic agents directly to the cancer cells while sparing healthy tissues.

What are the objectives of the ADCElerate-01 trial?

The trial aims to assess the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 in patients with metastatic and/or unresectable soft tissue sarcoma.

Who are the key researchers involved in the trial?

Dr. Lone Ottesen, Chief Medical Officer of Adcendo, and Prof. Patrick Schöffski from KU Leuven are leading the trial efforts, focusing on advancing treatment options for patients.

What other developments are underway at Adcendo?

Adcendo is working on expanding its pipeline of first-in-class ADCs, driven by recent funding to accelerate research and clinical development of their innovative therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 41

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
AutoMobility LA Puts 2028 Mobility on Center Stage

Updated Category News Views 98

Los Angeles is cramming an awful lot of automotive ambition into one Thursday. AutoMobility LA opens November 19 at the Los Angeles Convention Center, one day before the LA Auto Show begins its November 20–29 public run. Yes, there will be coffee carts, awards, creators and the usual event confetti. But beneath that polished show-floor racket sits a fairly serious...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 81

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 13

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 0

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 161

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 88

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 14

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 111

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Planning for Long-Term and Short-Term Financial Success

Updated Category Investing Views 1297

Financial success rarely happens by accident. It requires deliberate planning, disciplined execution, and ongoing adjustments to align with changing circumstances. People often focus either on their short-term needs or their long-term goals, overlooking the importance of balancing them. A strong financial strategy incorporates immediate priorities while building a secure...

Continue Reading
Anticipating Caesars Entertainment's Upcoming Earnings Report

Updated Category News Views 259

A Look Ahead at Caesars Entertainment's Earnings Report Caesars Entertainment (NASDAQ: CZR) is on the verge of revealing its quarterly earnings report, drawing the interest of investors and market analysts alike. With anticipation building, here’s what the market expects before the announcement. Projected Earnings and Market Reactions Market analysts predict that...

Continue Reading
ResVita Bio's FDA Meeting Marks Progress for Netherton Syndrome

Updated Category News Views 215

ResVita Bio Advances Clinical Plans for Netherton Syndrome ResVita Bio, a biotechnology company focused on groundbreaking treatment options for skin diseases, recently shared exciting news about a pivotal meeting with the U.S. Food and Drug Administration (FDA). This engagement was crucial as it involved RVB-003, their leading investigational therapy targeted at...

Continue Reading
Solidion Technology Innovates to Advance Lithium-Sulfur Batteries

Updated Category News Views 235

Solidion Technology Makes Significant Advances in Battery Technology Solidion Technology, Inc. (NASDAQ: STI) has made remarkable progress in the field of battery technology, particularly with its lithium-sulfur (Li-S) batteries. Recently, Solidion announced a breakthrough in achieving a cell energy density of 380 Wh/kg, with future ambitions set at reaching 450 Wh/kg....

Continue Reading
Luray Peanut Co. Spices Up Snack Market with New Launch

Updated Category News Views 76

Spice Meets Peanut In An Unexpected Fusion Alright, let's shed some light on the latest concoction shaking up the snacking aisle. Luray Peanut Company has teamed up with none other than Texas Pete® to create a spicy new twist on boiled peanuts. Trust me, this is no typical snack partnership. Instead, it's the kind of daring venture that screams Southern soul with a...

Continue Reading